You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Treatment Advances in NTRK Gene Fusion-Positive Sarcoma: What Do You Need to Know?

  • Authors: Jean-Yves Blay, MD, PhD; George D. Demetri, MD
  • CME / ABIM MOC Released: 12/15/2020
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/15/2021
Start Activity


Target Audience and Goal Statement

This activity is intended for oncologists.

The goal of this activity is to increase clinicians' understanding of recent advancements within NTRK gene fusion-positive sarcoma.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Biomarkers to guide treatment decisions in patients with NTRK gene fusion-positive sarcoma
    • Clinical trial data evaluating treatment options within NTRK gene fusion-positive sarcoma


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Jean-Yves Blay, MD, PhD

    Professor of Medical Oncology
    President, UNICANCER
    General Director, Centre Léon Bérard
    French Sarcoma Group, Académie Nationale de Médecine
    LYRICAN, NETSARC, ERN EURACAN
    Lyon, France

    Disclosures

    Disclosure: Jean-Yves Blay, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer; Bristol Myers Squibb; Deciphera; Merck Sharpe & Dohme; Pharmamar; Roche
    Received grants for clinical research from: Bayer; Bristol Myers Squibb; Deciphera; Merck Sharpe & Dohme; Pharmamar; Roche

  • George D. Demetri, MD

    Director, Sarcoma Center, Dana-Farber Cancer Institute
    Professor of Medicine and Co-Director, Ludwig Center at Harvard Medical School
    Boston, Massachusetts, United States

    Disclosures

    Disclosure: George D. Demetri, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bessor Pharmaceuticals; C4 Therapeutics; Caris Life Sciences; EMD Serono; Erasca Pharmaceuticals; G1 Therapeutics; GlaxoSmithKline; ICON plc; McCann Health; Mirati; MJ Hennessey/OncLive; Polaris; RELAY Therapeutics; Sanofi; Synlogic
    Received grants for clinical research from: AbbVie; AdaptImmune; Bayer; Dana-Farber; Daiichi Sankyo; Epizyme; GlaxoSmithKline; Janssen; LOXO Oncology; Novartis; Pfizer; PharmaMar; Roche/Genentech   
    Owns stock, stock options, or bonds from: Novartis royalty to Dana-Farber for use patent of imatinib in GIST
    Other: Board of Directors member and Scientific Advisory Board Consultant: Blueprint Medicines; GIST; Translate BIO

Editor

  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Megan Whitney, DMD, has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Regeneron


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Treatment Advances in NTRK Gene Fusion-Positive Sarcoma: What Do You Need to Know?

Authors: Jean-Yves Blay, MD, PhD; George D. Demetri, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 12/15/2020

Valid for credit through: 12/15/2021

processing....

 

 

  • Print